Psoriasis, a model of dermatologic psychosomatic disease: Psychiatric implications and treatments

International Journal of Dermatology

Volumn 51, Issue 1, 2012, Pages 12-26

  Rieder, Evan ^a   Tausk, Francisco ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL CONSUMPTION; ALEXITHYMIA; ANXIETY; COMORBIDITY; DEPRESSION; HUMAN; PSORIASIS; PSYCHOSOCIAL DISORDER; PSYCHOSOMATIC DISORDER; REVIEW; SEXUAL DYSFUNCTION; SMOKING; STRESS; SUICIDAL IDEATION; TREATMENT OUTCOME;

AFFECTIVE SYMPTOMS; ALCOHOL DRINKING; ANXIETY; DEPRESSION; FEMALE; HUMANS; MALE; PSORIASIS; PSYCHOPHYSIOLOGIC DISORDERS; PSYCHOTROPIC DRUGS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SMOKING; STRESS, PSYCHOLOGICAL; SUICIDE;

EID: 84055183390     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05071.x     Document Type: Review

References (105)

1. Kimball AB, Gladman D, Gelfand JM, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-1042.
2. Alsufyani MA, Golant AK, Lebwohl MG. Psoriasis and the metabolic syndrome. Dermatol Ther 2010; 23: 137-143.
3. Van Voorhees AS, Fried R. Depression and quality of life in psoriasis. Postgrad Med 2009; 121: 154-161.
4. Engel G. The need for a new medical model: a challenge for biomedicine. Science 1977; 196: 129-136.
5. Bahmer JA, Kuhl J, Bahmer F. How do personality systems interact in patients with psoriasis, atopic dermatitis and urticaria? Acta Derm Venereol 2007; 87: 317-324.
6. Gupta MA, Gupta AK, Haberman H. Psoriasis and psychiatry: an update. Gen Hosp Psychiatry 1987; 9: 157-166.
7. Magin PJ, Adams J, Heading GS, Pond C. Patients with skin disease and their relationships with their doctors: a qualitative study of patients with acne, psoriasis and eczema. Med J Aust 2009; 19: 62-64.
8. Fortune DG, Richards HL, Kirby B, et al. Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being. Br J Dermatol 2004; 151: 1219-1226.
9. Richards HL, Fortune DG, Weidmann A, et al. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol 2004; 151: 1227-1233.
10. Picardi A, Amerio P, Baliva G, et al. Recognition of depressive and anxiety disorders in dermatological outpatients. Acta Derm Venereol 2004; 84: 213-217.
11. Ginsburg I. Psychological and psychophysiological aspects of psoriasis. Dermatol Clin 1995; 13: 793-804.
12. Fortune DG, Richards HL, Griffiths C. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 2005; 23: 681-694.
13. Jafferany M. Psychodermatology: a guide to understanding common psychocutaneous disorders. Prim Care Companion J Clin Psychiatry 2007; 9: 203-213.
14. Levenson J. Psychiatric issues in dermatology, part 1: atopic dermatitis and psoriasis. Prim Psychiatry 2008; 15: 35-38.
15. Locala J. Current concepts in psychodermatology. Curr Psychiatry Rep 2009; 11: 211-218.
16. Koblenzer C. The emotional impact of chronic and disabling skin disease: a psychoanalytic perspective. Dermatol Clin 2005; 23: 619-627.
17. Ginsburg IH, Link B. Psychosocial consequences of rejection and stigma feelings in psoriasis. Int J Dermatol 1993; 32: 587-591.
18. Magin P, Adams J, Heading G, et al. The psychological sequelae of psoriasis: results of a qualitative study. Psychol Health Med 2009; 14: 150-161.
19. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-392.
20. Choi JC, Koo J. Quality of life issues in psoriasis. J Am Acad Dermatol 1993; 49: S57-S61.
21. Fried RG, Friedman S, Paradis C, et al. Trivial or terrible? The psychological impact of psoriasis Int J Dermatol 1995; 34: 101-105.
22. De Korte J, Sprangers MA, Mombers FM, Bos J. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 140-147.
23. Sampogna F, Tabolli S, Abeni D. The impact of changes in clinical severity on psychiatric morbidity in patients with psoriasis: a follow-up study. Br J Dermatol 2007; 157: 508-513.
24. Schmitt JM, Ford D. Role of depression in quality of life for patients with psoriasis. Dermatology 2007; 215: 17-27.
25. Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol 2010; 24: 885-892.
26. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis. Arch Dermatol 2010; 146: 891-895.
27. Consoli SM, Rolhion S, Martin C, et al. Low levels of emotional awareness predict a better response to dermatological treatment in patients with psoriasis. Dermatology 2006; 212: 128-136.
28. Karanikas E, Harsoulis F, Giouzepas I, et al. Neuroendocrine stimulatory tests of hypothalamus-pituitary-adrenal axis in psoriasis and correlative implications with psychopathological and immune parameters. J Dermatol 2009; 36: 35-44.
29. Kiliç A, Güleç MY, Gül Ü, Güleç H. Temperament and character profile of patients with psoriasis. J Eur Acad Dermatol Venereol 2008; 22: 537-542.
30. Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006; 212: 123-127.
31. Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther 2010; 23: 174-180.
32. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-741.
33. Schon MP, Boehneke WH. Psoriasis. N Engl J Med 2005; 352: 1899-1912.
34. Harth W, Gieler U, Kusnir D, Tausk F. Clinical Management in Psychodermatology. Leipzig: Springer-Verlag, 2009.
35. Gupta MA, Gupta A. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846-850.
36. Zachariae R, Zachariae C, Ibsen HH, et al. Psychological symptoms and quality of life in dermatology outpatients and hospitalized dermatology patients. Acta Derm Venereol 2004; 84: 205-212.
37. Gupta MA, Schnork NJ, Gupta AK, et al. Suicidal ideation in psoriasis. Int J Dermatol 1993; 32: 188-190.
38. Picardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol 2006; 54: 420-426.
39. Evers AW, Lu Y, Duller P, et al. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis Br J Dermatol 2005; 152: 1275-1281.
40. Gupta MA, Gupta A. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol 1997; 36: 259-262.
41. Türel Ermertcan A, Temeltaş G, Deveci A, et al. Sexual dysfunction in patients with psoriasis. J Dermatol 2006; 33: 772-778.
42. Mercan S, Altunay IK, Demir B, et al. Sexual dysfunctions in patients with neurodermatitis and psoriasis. J Sex Marital Ther 2008; 34: 160-168.
43. Sampogna F, Gisondi P, Tabolli S, Abeni D. Impairment of sexual life in patients with psoriasis. Dermatology 2007; 214: 144-150.
44. Magin P, Heading G, Adams J, Pond D. Sex and the skin: a qualitative study of patients with acne, psoriasis and atopic eczema. Psychol Health Med 2010; 15: 454-462.
45. Goulding JM, Price CL, Defty CL, et al. Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene. Br J Dermatol 2011; 164: 103-109.
46. Setty AR, Curhan G, Choim H. Smoking and the risk of psoriasis in women: Nurses' health study II. Am J Med 2007; 120: 953-959.
47. La Vecchia C, Gallus S, Naldi L. Tobacco and skin disease. Dermatology 2005; 211: 81-83.
48. Richter-Hintz D, Their R, Steinwachs S, et al. Allelic variants of drug metabolizing enzymes as risk factors in psoriasis. J Invest Dermatol 2003; 120: 765-770.
49. Krämer U, Esser C. Cigarette smoking, metabolic gene polymorphism, and psoriasis. J Invest Dermatol 2006; 126: 693-694.
50. Behnam SM, Behnam SE, Koo J. Smoking and psoriasis. Skinmed 2005; 4: 174-176.
51. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534.
52. Fortes C, Mastroeni S, Leffondré K, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005; 141: 1580-1584.
53. Favato G. High incidence of smoking habit in psoriatic patients. Am J Med 2008; 121: e17.
54. Jankovic S, Raznatovic M, Marinkovic J, et al. Risk factors for psoriasis: a case-control study. J Dermatol 2009; 36: 328-334.
55. Huerta C, Rivero E, Garcia Rodriguez L. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559-1565.
56. Behnam SM, Behnam SE, Koo J. Alcohol as a risk factor for plaque-type psoriasis. Cutis 2005; 76: 181-185.
57. Braathen LR, Botten G, Bjerkedal T. Psoriatics in Norway. A questionnaire study on health status, contact with paramedical professionals, and alcohol and tobacco consumption. Acta Derm Venereol Suppl (Stockh) 1989; 142: 9-12.
58. Lindegard B. Diseases associated with psoriasis in a general population of 159, 200 middle-aged, urban, native Swedes. Dermatolgica 1986; 172: 298-304.
59. Farkas A, Kemeny L. Psoriasis and alcohol: is cutaneous ethanol one of the missing links? Br J Dermatol 2010; 162: 711-716.
60. Szabo G, Mandrekar P. A recent perspective on alcohol, immunity, and host defense. Alcohol Clin Exp Res 2009; 33: 220-232.
61. Brand R, Jendrzejewski J, Henery E, Charron A. A single oral dose of ethanol can alter transdermal absorption of topically applied chemicals in rats. Toxicol Sci 2006; 92: 349-355.
62. Sakai J, Mikulich-Gilbertson S, Long R, Crowley T. Validity of transdermal alcohol monitoring: fixed and self-regulated dosing. Alcohol Clin Exp Res 2006; 30: 26-33.
63. Bø K, Thoesen M, Dalgard F. Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a Norwegian population survey among adults. Dermatology 2008; 216: 40-45.
64. Qureshi AA, Dominguez PL, Choi HK, et al. Alcohol intake and risk of incident psoriasis in us women. Arch Dermatol 2010; 146: 1364-1369.
65. Kirby B, Richards HL, Mason DL, et al. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 2008; 158: 138-140.
66. Dediol I, Buljan M, Buljan D, et al. Association of psoriasis and alcoholism: psychodermatological issue. Psychiatr Danub 2009; 21: 9-13.
67. Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001; 50: 11-15.
68. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000; 14: 267-271.
69. Taner E, Coşar B, Burhanoǧlu S, et al. Depression and anxiety in patients with Behçet's disease compared with that in patients with psoriasis. Int J Dermatol 2007; 46: 1118-1124.
70. Tausk F, Elenkov I, Moynihan J. Psychoneuroimmunology. Dermatol Ther 2008; 21: 22-31.
71. Simonic E, Kaštelan M, Peternel S, et al. Childhood and adulthood traumatic experiences in patients with psoriasis. J Dermatol 2010; 37: 793-800.
72. Picardi A, Pasquini P, Cattaruzza MS, et al. Only limited support for a role of psychosomatic factors in psoriasis. Results from a case-control study. J Psychosom Res 2003; 55: 189-196.
73. Berg M, Svensson M, Brandberg M, Nordlind K. Psoriasis and stress: a prospective study. J Eur Acad Dermatol Venereol 2008; 22: 670-674.
74. Garg A, Chren MM, Sands LP, et al. Psychological stress perturbs epidermal permeability barrier homeostasis. Arch Dermatol 2001; 137: 53-59.
75. Fortune DG, Richards HL, Kirby B, et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 2003; 139: 752-756.
76. Gaston L, Lassonde M, Bernier-Buzzanga J, et al. Psoriasis and stress: a prospective study. J Am Acad Dermatol 1987; 17: 82-86.
77. Richards HL, Ray DW, Kirby B, et al. Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol 2005; 153: 1114-1120.
78. Verhoeven EWM, Kraaimaat FW, de Jong EM, et al. Individual differences in the effect of daily stressors on psoriasis: a prospective study. Br J Dermatol 2009; 161: 295-299.
79. Verhoeven EWM, Kraaimaat FW, de Jong EM, et al. Effect of daily stressors on psoriasis: a prospective study. J Invest Dermatol 2009; 129: 2075-2077.
80. Willemsen R, Roseeuw D, Vanderlinden J. Alexithymia and dermatology: the state of the art. Int J Dermatol 2008; 47: 903-910.
81. Fried RG, Hussain S. Nonpharmacologic management of common skin and psychocutaneous disorders. Dermatol Ther 2008; 21: 60-68.
82. Fortune DG, Richards HL, Kirby B, et al. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 2002; 146: 458-465.
83. Kabat-Zinn J, Wheeler E, Light T, et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med 1998; 60: 625-632.
84. Tausk F, Whitmore S. A pilot study of hypnosis in the treatment of patients with psoriasis. Psychother Psychosom 1999; 68: 221-225.
85. Ader R, Mercurio M, Walton J, et al. Conditioned pharmacotherapeutic effects: a preliminary study. Psychosom Med 2009; 72: 192-197.
86. Alpsoy E, Ozcan E, Cetin L, et al. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study J Am Acad Dermatol 1998; 38: 197-200.
87. Modell JG, Boyce S, Taylor E, Katholi C. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-sr: a pilot study. Psychosom Med 2002; 64: 835-840.
88. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 2006; 367: 29-35.
89. Gelfand J, Kimball A, Mostow E, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008; 11: 400-407.
90. Langley RG, Feldman SR, Chenglong H, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457-465.
91. Cox NH, Goron PM, Dodd H. Generalized pustular and erythrodermic psoriasis associated with bupropion treatment. Br J Dermatol 2002; 146: 1061-1063.
92. Blay S. Depression and psoriasis comorbidity. Treatment with paroxetine: two case reports. Ann Clin Psychiatry 2006; 18: 271-272.
93. Hemlock C, Rosenthal JS, Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother 1992; 26: 211-212.
94. Tamer E, Gur G, Polat M, Alli N. Flare-up of pustular psoriasis with fluoxetine: possibility of a serotoninergic influence? J Dermatolog Treat 2009; 20: 1-3.
95. Thorslund K, El-Nour H, Nordlind K. The serotonin transporter protein is expressed in psoriasis, where it may play a role in regulating apoptosis. Arch Dermatol Res 2009; 301: 449-457.
96. Bassukas ID, Hyphantis T, Gamvroulia C, et al. Infliximab for patients with plaque psoriasis and severe psychiatric comorbidity. J Eur Acad Dermatol Venereol 2008; 22: 257-258.
97. Immunex Corporation. Enbrel® (etanercept) [package insert]. Thousand Oaks, CA: Immunex Corporation, 2010.
98. Pietrzak AT, Zalewska A, Chodorowska G, et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta 2008; 394: 7-21.
99. Zhu CB, Blakely RD, Hewlett W. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006; 31: 2121-2131.
100. Krishnan R, Cella D, Leonardi C, et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007; 157: 1275-1277.
101. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-592.
102. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind placebo-controlled trial (phoenix 1). Lancet 2008; 371: 1665-1674.
103. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale: an updated literature review. J Psychosom Res 2002; 52: 69-77.
104. Silverstone PH. Poor efficacy of the hospital anxiety and depression scale in the diagnosis of major depressive disorder in both medical and psychiatric patients. J Psychosom Res 1994; 38: 441-450.
105. Moynihan J, Rieder E, Tausk F. Psychoneuroimmunology: the example of psoriasis. G Ital Dermatol Venereol 2010; 145: 221-228.